, a bio/informatics shared resource is still "open for business" - Visit the CDS website

Developments and controversies in the management of noninvasive bladder cancer.

Bassett JC, Eifler JB, Resnick MJ, Clark PE
Curr Opin Oncol. 2014 26 (3): 299-304

PMID: 24638080 · DOI:10.1097/CCO.0000000000000067

PURPOSE OF REVIEW - To summarize recent developments and controversies in the diagnosis and management of nonmuscle invasive bladder cancer (NMIBC).

RECENT FINDINGS - The majority of incident bladder cancer diagnoses are noninvasive. The mainstay of diagnosis remains cystoscopy and transurethral resection, with enhanced optical techniques potentially improving detection of nascent disease. Intravesical chemotherapeutic and immunotherapeutic agents reduce the likelihood of recurrence and progression, with novel agents showing promise. The identification of variant histology with aggressive phenotypes permits identification of patients unlikely to respond to intravesical agents, in whom early cystectomy is advocated. Risk stratification of patients with NMIBC continues to improve and should be used to inform surveillance and treatment paradigms. Tobacco cessation may improve disease-specific endpoints and overall mortality.

SUMMARY - NMIBC encompasses a variety of tumors with heterogeneous natural histories, making clinical management challenging. Improved detection with novel technologies and optimization of existing treatment modalities hold promise of improving oncologic outcomes in the future.

MeSH Terms (8)

Administration, Intravesical Antineoplastic Agents Cystectomy Cystoscopy Diagnostic Techniques, Urological Humans Risk Assessment Urinary Bladder Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities: